These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23352776)

  • 1. A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.
    Wang CH; Li Y; Yang J; Su LY; Geng YG; Li H; Wang JK; Mu JL
    Schizophr Res; 2013 Mar; 144(1-3):129-35. PubMed ID: 23352776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginine vasopressin improves the memory deficits in Han Chinese patients with first-episode schizophrenia.
    Geng CH; Wang C; Yang J; Wang H; Ma RQ; Liu X; Wang CH
    Peptides; 2017 Nov; 97():8-15. PubMed ID: 28882471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.
    Witte MM; Case MG; Schuh KJ; Ascher-Svanum H
    Curr Med Res Opin; 2012 Mar; 28(3):315-23. PubMed ID: 22236137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
    Dossenbach MR; Folnegovic-Smalc V; Hotujac L; Uglesic B; Tollefson GD; Grundy SL; Friedel P; Jakovljevic MM;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):311-8. PubMed ID: 14751428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
    Krakowski MI; Czobor P; Nolan KA
    J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.
    Takeuchi H; Suzuki T; Remington G; Bies RR; Abe T; Graff-Guerrero A; Watanabe K; Mimura M; Uchida H
    Schizophr Bull; 2013 Sep; 39(5):993-8. PubMed ID: 23821768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of olanzapine treatment on cognitive functions in patients with schizophrenia].
    Radziwiłłowicz P; Radziwiłłowicz W; Lis J
    Psychiatr Pol; 2002; 36(6):967-87. PubMed ID: 12725025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders.
    Korostenskaja M; Dapsys K; Siurkute A; Maciulis V; Ruksenas O; Kähkönen S
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):543-8. PubMed ID: 15866356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.
    Higuchi Y; Sumiyoshi T; Kawasaki Y; Matsui M; Arai H; Kurachi M
    Schizophr Res; 2008 Apr; 101(1-3):320-30. PubMed ID: 18321680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic drug effects on brain morphology in first-episode psychosis.
    Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
    Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM; Yang R; Youakim JM
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of olanzapine treatment on brain regional glucose metabolism in neuroleptic-naive first-episode schizophrenic patients.
    Yoshimuta H; Nakamura M; Kanda E; Fujita S; Takeuchi K; Fujimoto T; Nakabeppu Y; Akasaki Y; Sano A
    Hum Psychopharmacol; 2016 Nov; 31(6):419-426. PubMed ID: 27859668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients.
    Zhang XY; Chen DC; Xiu MH; Yang FD; Haile CN; Kosten TA; Kosten TR
    J Clin Psychiatry; 2012 Jul; 73(7):1025-33. PubMed ID: 22901352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.